1. ALLA AKTIER
  2. NYHETER
  3. AMNIOTICS

Amniotics

Nyheter Amniotics Nyheter alla bolag
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!

Liquidity providing agreement terminated

MARKN.

Amniotics AB (publ) has terminated its agreement with Lago Kapital regarding liquidity providing for the company's shares. The purpose of the liquidity providing was to promote the share's liquidity and reduce its volatility, thereby facilitating share trading. The company believes that the liquidity providing is no longer needed. The agreement expires on January 5, 2023.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

or
Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now in clinical phase with the leading drug candidate PulmoStem™. The company is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm.
Amniotics Certified Adviser at First North is Redeye AB, e-post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com. 

Attachments

Liquidity providing agreement terminated

Datum 2022-12-08, kl 07:45
Källa MFN
Bifogade filer
Liquidity providing agreement terminated